Drug
TQB2450(blank)
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_3
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Other(2)
Detailed Status
unknown2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 32 (100.0%)
Trials by Status
unknown2100%
Recent Activity
0 active trials
Showing 2 of 2
unknownphase_3
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
NCT04325763
unknownphase_3
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
NCT04234607
Clinical Trials (2)
Showing 2 of 2 trials
NCT04325763Phase 3
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
NCT04234607Phase 3
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2